For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Take a look at our BETA site and see what we’ve done so far.
Search and browse selected products
Purchase these through your usual distributor
This series of interactive digital sessions is dedicated to the latest breakthroughs in ovarian cancer resistance, the epigenetics of Acute Myeloid Leukemia, and the earlier detection of pancreatic cancer. Revisit insights from the live sessions through the on-demand recordings - available below.
Acute myeloid leukemia (AML) exhibits significant genetic and transcriptional heterogeneity. Modulating epigenetics shows increasing potential in tackling unmet clinical needs in AML. Get up to speed with recent advances, challenges and future therapeutic directions in the epigenetic landscape of AML.
Moderator and speakers:
Not available on-demand:
Why do some ovarian cancers respond to treatment, while others do not? Why do some respond at first, then become resistant? In this session, we will be discussing hot topics, such as overcoming carboplatin resistance, increasing the success of immunotherapies, and the need for better biomarkers.
Moderator and speakers:
Not available on-demand:
'Non-genetic heterogeneity defines chemotherapy resistance of minimal residual disease in high grade serous ovarian cancer'
Early detection of hard-to-treat cancers, such as pancreatic cancer, is critical for improving overall survival. In this session, we will be discussing areas of greatest need, such as the most promising biomarkers, challenges for clinical adoption, and much more.
Moderator and speakers
'Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer'